Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
Adult
Anti-Allergic Agents
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Asthma
/ drug therapy
Biomarkers
Double-Blind Method
Eosinophils
/ cytology
Female
Forced Expiratory Volume
/ drug effects
Humans
Immunoglobulin E
/ blood
Male
Middle Aged
Quality of Life
Receptors, Interleukin-4, Type II
/ antagonists & inhibitors
Rhinitis, Allergic, Perennial
/ drug therapy
Journal
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
23
04
2020
accepted:
21
05
2020
pubmed:
1
6
2020
medline:
15
12
2020
entrez:
1
6
2020
Statut:
ppublish
Résumé
Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of type 2 inflammation that play important roles in asthma and PAR. In the LIBERTY ASTHMA QUEST trial (NCT02414854), dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV To assess dupilumab efficacy in LIBERTY ASTHMA QUEST patients with comorbid PAR. Severe asthma exacerbation rates, FEV A total of 814 of the 1902 patients (42.8%) had comorbid PAR (defined as an allergic rhinitis history and ≥1 perennial aeroallergen specific immunoglobulin E (IgE) level ≥0.35 kU/L at baseline). Dupilumab, 200 and 300 mg every 2 weeks, vs placebo reduced severe exacerbations rates by 32.2% and 34.6% (P < .05 for both) and improved FEV Dupilumab improved key asthma-related outcomes, asthma control, and rhinoconjunctivitis-specific health-related quality of life while suppressing type 2 inflammatory biomarkers and perennial allergen-specific IgE in patients with moderate-to-severe asthma and comorbid PAR, highlighting its dual inhibitory effects on IL-4 and IL-13 and its role in managing asthma and PAR.
Sections du résumé
BACKGROUND
Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of type 2 inflammation that play important roles in asthma and PAR. In the LIBERTY ASTHMA QUEST trial (NCT02414854), dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV
OBJECTIVE
To assess dupilumab efficacy in LIBERTY ASTHMA QUEST patients with comorbid PAR.
METHODS
Severe asthma exacerbation rates, FEV
RESULTS
A total of 814 of the 1902 patients (42.8%) had comorbid PAR (defined as an allergic rhinitis history and ≥1 perennial aeroallergen specific immunoglobulin E (IgE) level ≥0.35 kU/L at baseline). Dupilumab, 200 and 300 mg every 2 weeks, vs placebo reduced severe exacerbations rates by 32.2% and 34.6% (P < .05 for both) and improved FEV
CONCLUSION
Dupilumab improved key asthma-related outcomes, asthma control, and rhinoconjunctivitis-specific health-related quality of life while suppressing type 2 inflammatory biomarkers and perennial allergen-specific IgE in patients with moderate-to-severe asthma and comorbid PAR, highlighting its dual inhibitory effects on IL-4 and IL-13 and its role in managing asthma and PAR.
Identifiants
pubmed: 32474156
pii: S1081-1206(20)30389-6
doi: 10.1016/j.anai.2020.05.026
pii:
doi:
Substances chimiques
Anti-Allergic Agents
0
Antibodies, Monoclonal, Humanized
0
Biomarkers
0
Receptors, Interleukin-4, Type II
0
Immunoglobulin E
37341-29-0
dupilumab
420K487FSG
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-576.e1Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.